Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
5-플루오로-2'-디옥시유리딘
5-플루오로-2'-디옥시유리딘 · FUDR · FDUR · 5-FLUORODEOXYURIDINE · 5-FUDR · 5-Fluoro-1-((2R,4S,5R)-4-hydroxy-5-(hydroxyMethyl)tetrahydrofuran-2-yl)pyriMidine-2,4(1H,3H)-dione · 5-FLUORO-2-DEOXYURIDINE · 2'-Deoxy-5-fluorouridine

식별자 및 물리적 특성
| CAS No. | 50-91-9 |
|---|---|
| 분자식 | C9H11FN2O5 |
| 평균 분자량 | 246.19 g/mol |
| 단동위원소 질량 | 246.06519967 g/mol |
| SMILES | O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1F |
| InChIKey | ODKNJVUHOIMIIZ-RRKCRQDMSA-N |
| PubChem CID | 5790 |
| ChEMBL | CHEMBL917 |
| ChEBI | CHEBI:60761 |
| EC No. | 200-072-5 |
| DTXSID | DTXSID3023057 |
| 현지명 | 5-플루오로-2'-디옥시유리딘 |
화학 및 물리적 성질
| XLogP | -1.2 |
|---|---|
| 극성 표면적 | 99.1 |
| 수소 결합 공여자 수 | 3 |
| 수소 결합 수용자 수 | 6 |
| 회전 가능 결합 수 | 2 |
| 무거운 원자 수 | 17 |
| 형식 전하 | 0 |
| 복잡도 | 386 |
| 의약품 | Pharmaceuticals -> Anti infectives for systemic use -> Antivirals for systemic usePharmaceuticals -> Listed in ZINC15 |
| LogP(분배 계수) | log Kow = -1.16-1.4 |
| 냄새 | ODORLESS |
| Color/Form | Crystals from butyl acetateWHITE TO OFF-WHITE SOLID |
| 용해도 | 1 g in about 4.5 ml isopropanol, about 7.5 ml methanol, about 12 ml alcohol, about 27 ml acetoneinsol in chloroform, ether, and benzene4.08e+01 g/LSoluble to 100 mM in water and to 100 mM in DMSO |
| Human Drugs | FDA approved drugs -> Active ingredient |
| Decomposition | When heated to decomposition it emits very toxic fumes of /hydrogen fluoride and nitrogen oxides/. |
| 녹는점 | 302 to 304 °F (NTP, 1992)150-151 °C150.5 °C148 °C(lit.) |
| Optical Rotation | Crystals from butyl acetate, mp 150-151 °C. Specific optical rotation at 25 °C for D (sodium) line = -21 deg (c = 2 in water) /alpha-Anomer/Specific optical rotation for D (sodium) line = +37 deg (water)+48.6 deg (DMF) |
| Physical Description | Inhibits DNA synthesis. (NTP, 1992)Solid |
| Dissociation Constants | 7.44pKa = 7.44 (imide nitrogen) |
| 끓는 점 | 150 °C |
| 밀도 | 1.3751 (estimate) |
| 저장 조건 | room temp |
| pKa(산도 계수) | pKa 7.44 (Uncertain) |
| 물리적 상태 | 가루 |
| 색상 | 흰색에서 거의 흰색 |
| 생물학적 소스 | synthetic (organic) |
| 용해도 | 녹는 |
| Merck | 14,4112 |
| BRN | 2645818 |
| 안정성 | 안정적인. 강한 산화제와 호환되지 않습니다. |
| 주요 응용 | 소분자 약용 |
| InChI | 1S/C9H11FN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)/t5-,6+,7+/m0/s1 |
| InChIKey | ODKNJVUHOIMIIZ-GFCOJPQKSA-N |
| SMILES | OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(F)C(=O)NC2=O |
| NIST | Uridine, 2'-deoxy-5-fluoro-(50-91-9) |
| EPA | Floxuridine (50-91-9) |
화학적 성질
White Solid
안전 및 규제
| GHS 분류 | DangerH301 (96.1%): Toxic if swallowed [Danger Acute toxicity, oral]P203, P264, P270, P280, P301+P316, P318, P321, P330, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 51 reports by companies from 7 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| 규제 정보 | Floxuridine: Does not have an individual approval but may be used under an appropriate group standard |
| 운송 라벨(DOT) | Corrosive |
| 화재 위험 | Flash point data for this chemical are not available, but it is probably combustible. (NTP, 1992) |
| 건강 유해성 | ACUTE/CHRONIC HAZARDS: This material is highly toxic by ingestion. (NTP, 1992) |
| FDA 요건 | The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl floxuridine, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. |
| 반응성 그룹 | Alcohols and Polyols |
| Air and Water Reactions | No rapid reaction with air. No rapid reaction with water. |
| Hazard Classes and Categories | Acute Tox. 3 (96.1%) |
| 소화 | Fires involving this compound should be controlled with a dry chemical, carbon dioxide or Halon extinguisher. (NTP, 1992) |
| 응급 처치 | EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop. |
| 보관 조건 | Floxuridine sterile powder should be protected from light and stored at 15-30 °C. In the dry state, floxuridine has an expiration date of 3 years following the date of manufacture. Reconstituted floxuridine injection should be stored at 2-8 °C and used within 2 weeks. |
용도
용도
Floxuridine USP is used in Palliative treatment of gastrointestinal adenocarcinoma with liver metastases.
일반 설명
Inhibits DNA synthesis.